Skip to content
Markets News
Stocks1 min read

FDA Clears Regeneron’s Four-Times-Yearly gMG Treatment

Makkler Newsroom
November 19, 2026 · Based on reporting by GlobeNewswire

Livsayis won approval for adults with anti-AChR-positive generalized myasthenia gravis, based on Phase 3 results reported by Regeneron.

Key takeaways

  • The FDA approved Livsayis for adults with anti-AChR-positive generalized myasthenia gravis.
  • In the Phase 3 trial, the drug improved MG-ADL scores by 4.5 points at 24 weeks, versus 2.2 for placebo.

Regeneron said the FDA approved Livsayis for adults with anti-AChR-positive generalized myasthenia gravis. The company says it is the first approved siRNA therapy for the condition and the only FDA-approved gMG treatment given by under-the-skin injection four times a year.

The decision was based on the Phase 3 NIMBLE trial. At 24 weeks, the drug improved patients’ MG-ADL scores by 4.5 points on average, compared with 2.2 points for placebo, according to Regeneron.

The drug’s prescribing information carries a boxed warning about serious meningococcal infections. Livsayis is available through a restricted safety program, the company said.

A regulatory submission for the treatment is under review in the European Union, with a decision anticipated in the second half of 2027.

Topics
REGNLivsayis

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.